This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Mental retardation	*Tumor suppressor candidate 3* (*TUSC3*; *N33*); *magnesium transporter 1* (*MAGT1*; *IAP*)	*In vitro* studies suggest that mutations in the *TUSC3* and *IAP* genes could be useful for diagnosing nonsyndromic mental retardation. Both genes code for a subunit of the oligosaccharyltransferase (OTase) complex, which catalyzes a key step in protein *N*-glycosylation. Further studies are needed to determine both the biological effects of the mutations and how defects in OTase can nevertheless result in normal cellular *N*-glycosylation. Ikonisys Inc. and Sequenom Inc. each have genetic tests for diseases associated with mental retardation in pilot trials.	Patent and licensing status undisclosed	Molinari, F. *et al. Am. J. Hum. Genet.*; published online May 1, 2008; doi:10.1016/j.ajhg.2008.03.021 **Contact:** Laurence Colleaux, Université Paris Descartes, Paris, France e-mail: colleaux@necker.fr